Integral Health Asset Management LLC lifted its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) by 19.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 238,000 shares of the biotechnology company's stock after purchasing an additional 38,000 shares during the quarter. Integral Health Asset Management LLC's holdings in Aclaris Therapeutics were worth $4,103,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of ACRS. Point72 Hong Kong Ltd acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter worth approximately $26,000. BNP Paribas Arbitrage SA grew its holdings in shares of Aclaris Therapeutics by 20.2% during the 4th quarter. BNP Paribas Arbitrage SA now owns 10,852 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 1,823 shares in the last quarter. Ensign Peak Advisors Inc acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter worth approximately $160,000. Blair William & Co. IL grew its holdings in shares of Aclaris Therapeutics by 27.4% during the 4th quarter. Blair William & Co. IL now owns 12,800 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 2,750 shares in the last quarter. Finally, OLD Mission Capital LLC acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter worth approximately $228,000. Institutional investors and hedge funds own 95.08% of the company's stock.
Get
Aclaris Therapeutics alerts:
Insider Activity
In related news, Director Andrew N. Schiff sold 19,565 shares of the business's stock in a transaction that occurred on Friday, June 17th. The shares were sold at an average price of $15.14, for a total transaction of $296,214.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.70% of the company's stock.
Aclaris Therapeutics Stock Down 0.6 %
NASDAQ:ACRS traded down $0.10 during trading hours on Monday, hitting $17.12. 10,127 shares of the stock were exchanged, compared to its average volume of 434,391. The company's 50 day moving average is $15.84 and its two-hundred day moving average is $15.00. Aclaris Therapeutics, Inc. has a twelve month low of $9.26 and a twelve month high of $19.97.
Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.05. The business had revenue of $1.53 million for the quarter, compared to analyst estimates of $1.59 million. Aclaris Therapeutics had a negative return on equity of 40.14% and a negative net margin of 1,355.98%. On average, analysts anticipate that Aclaris Therapeutics, Inc. will post -1.47 EPS for the current year.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the stock. William Blair reissued an "outperform" rating on shares of Aclaris Therapeutics in a report on Wednesday, May 11th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Aclaris Therapeutics in a research report on Monday, August 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Aclaris Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $38.00.
Aclaris Therapeutics Profile
(Get Rating)
Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
Read More
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating).
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
